FROM PRESS
to presentations

News

February 18, 2022
REVALESIO ANNOUNCES THE DESIGN OF RESCUE, A PHASE 2 TRIAL OF RNS60 IN ACUTE ISCHEMIC STROKE, AND THE PRESENTATION OF PRECLINICAL DATA AT THE INTERNATIONAL STROKE CONFERENCE 2022
DECEMBER 7, 2021
PROMISING CLINICAL DATA ON REVALESIO'S RNS60 PRESENTED AT 32ND INTERNATIONAL SYMPOSIUM ON ALS/MND
FEBRUARY 23, 2021
REVALESIO SIGNS AGREEMENT TO DESIGN TRIAL WITH RNS60 FOR THE HEALEY ALS PLATFORM TRIAL
All news

Publications

March 2023
RNS60 induces expression of DJ-1, an important protein in Parkinson's disease, in neuronal cells
June 2020
RNS60 HAS THERAPEUTIC EFFECTS IN A MOUSE MODEL OF TRAUMATIC BRAIN INJURY (TBI)
March 2019
RNS60 TREATMENT WAS WELL TOLERATED IN AN OPEN LABEL CLINICAL PILOT STUDY IN ALS
All Publications